P&K Skin Research Center Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 1/6
P&K Skin Research Center's earnings have been declining at an average annual rate of -11.9%, while the Life Sciences industry saw earnings growing at 31.2% annually. Revenues have been declining at an average rate of 1.9% per year. P&K Skin Research Center's return on equity is 7.1%, and it has net margins of 32.9%.
Wichtige Informationen
-11.9%
Wachstumsrate der Gewinne
-11.1%
EPS-Wachstumsrate
| Life Sciences Wachstum der Industrie | 53.7% |
| Wachstumsrate der Einnahmen | -1.9% |
| Eigenkapitalrendite | 7.1% |
| Netto-Marge | 32.9% |
| Letzte Ertragsaktualisierung | 30 Jun 2024 |
Jüngste Aktualisierungen vergangener Leistungen
Aufschlüsselung der Einnahmen und Ausgaben
Wie P&K Skin Research Center Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 30 Jun 24 | 16,283 | 5,356 | 3,933 | 1,457 |
| 31 Mar 24 | 15,500 | 4,697 | 4,066 | 1,400 |
| 31 Dec 23 | 14,843 | 4,813 | 3,998 | 1,357 |
| 30 Sep 23 | 15,766 | 5,323 | 3,972 | 1,508 |
| 30 Jun 23 | 16,602 | 6,080 | 3,805 | 1,636 |
| 31 Mar 23 | 17,740 | 7,170 | 3,590 | 1,675 |
| 31 Dec 22 | 17,957 | 7,130 | 3,476 | 1,670 |
Qualität der Erträge: A347740 has high quality earnings.
Wachsende Gewinnspanne: A347740's current net profit margins (32.9%) are lower than last year (36.6%).
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: Unable to establish if A347740's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Beschleunigtes Wachstum: Unable to compare A347740's past year earnings growth to its 5-year average as it has been trading publicly for less than 3 years.
Erträge im Vergleich zur Industrie: A347740 had negative earnings growth (-11.9%) over the past year, making it difficult to compare to the Life Sciences industry average (18%).
Eigenkapitalrendite
Hohe Eigenkapitalrendite: A347740's Return on Equity (7.1%) is considered low.